Ask about this productRelated genes to: RANBP5 antibody
- Gene:
- IPO5 NIH gene
- Name:
- importin 5
- Previous symbol:
- KPNB3, RANBP5
- Synonyms:
- IMB3, MGC2068, Pse1
- Chromosome:
- 13q32.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-06-09
- Date modifiied:
- 2014-11-19
Related products to: RANBP5 antibody
Related articles to: RANBP5 antibody
- This study aimed to use a shotgun proteomics approach to investigate proteome changes between two finishing diets (pasture or concentrate) and two meat aging methods (wet- or dry-aging) in 60 striploins (Longissimus thoracis et lumborum) from British breed steers (n = 15 from pasture and n = 15 from concentrate). Bag dry-aging led to higher abundances of proteins involved in muscle structure, energy metabolism, and proteolysis. Meanwhile, bag wet-aging led to increased levels of heat shock proteins (HSPs) and proteins associated with oxidative stress, suggesting a response to environmental stressors during aging. Concentrate-finished beef exhibited greater levels of glycolytic enzymes, which may contribute to improved tenderness and color stability, indicating a shift toward anaerobic metabolism. Pasture-finished beef increased the abundance of oxidative metabolism proteins, aligning with the greater physical activity of grass-fed cattle. TPM1, PGK1, TNNT3, GAPDH, ATP2A3, and PYGM were the top putative protein biomarkers in concentrate and dry-aged beef, followed by the overabundance of MYH7B in concentrate and wet-aged beef, with RPL23AY and IPO5 being the most significant in the combination of pasture-finished beef and wet-aging. This research provided a comprehensive understanding of how beef aging method and feeding systems influence the beef proteomes from wet- and dry-aging. It further identified, using PLS-DA-based chemometrics analysis, putative proteins as key discriminating biomarkers that warrant further investigation for dry-aged beef quality monitoring and authenticity. - Source: PubMed
Publication date: 2026/05/01
Correa DanielaAlessandroni LauraBrito GustavoDel Campo MarciaLuzardo SantiagoBravo Susana Bde Souza GuillermoÁlvarez CarlosFont-I-Furnols MariaGagaoua Mohammed - Chronic cadmium exposure is linked to esophageal squamous cell carcinoma (ESCC) progression, treatment resistance, and poor prognosis, but its molecular mechanisms remain unclear. Based on whole-transcriptome sequencing (RNA-seq) on chronic cadmium-treated (CCT) and untreated human EC109 ESCC cells, we performed lncRNA-mRNA co-expression and protein-protein interaction (PPI) network analyses to screen the hub genes related to cadmium exposure. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses depicted that these genes were mainly enriched in nucleocytoplasmic transport, ferroptosis, Huntington disease, and cellular senescence. Based on the lncRNA-miRNA-mRNA potential interaction, three lncRNAs (AC107068.1, TTN-AS1, MAPKAPK5-AS1) and ten mRNAs (IPO5, NUDCD1, OSTM1, CCNB1, FANCD2, TFRC, POLR2B, HTT, NUP43, NBN) were selected for competitive endogenous RNA (ceRNA) network construction. Connectivity map (CMap) analysis for the target mRNAs showed that JAK3-inhibitor-I was the most promising therapeutic drug for cadmium-induced ESCC progression. The prognostic value and abnormal expression of the candidate mRNAs were then validated in TCGA cohorts, cadmium-treated cancer cells and 41 ESCC specimens. Moreover, migration and invasion assays were performed to assess the effects of the identified gene on cell malignant phenotypes. As a result, IPO5 was identified as the pivotal gene and MAPKAPK5-AS1-hsa-miR-379-5p-IPO5 was deemed as a potential ceRNA regulatory mechanism for cadmium carcinogenesis in ESCC. Using TIMER and EPIC algorithms, IPO5 was correlated with increased infiltration of CD4+ T cells and macrophages, while negatively associated with CD8+ T cells and NK cells in ESCC tissues. Collectively, our study provides valuable information in understanding the molecular mechanisms involved in cadmium-induced ESCC progression and treatment resistance. Furthermore, we predict potential agents for cadmium carcinogenicity prevention and treatment. - Source: PubMed
Publication date: 2025/12/25
Zhu RuiChen JiongyuZhang XiarongChen QianJin YingmingZeng MingqinLuo JiananHuang YitengPeng Lin - The highly conserved nuclear transport protein importin 5 (IPO5) binds cargo implicated in fundamental processes including virus and chromatin assembly, germline development, and cell signaling. It also anchors cell-specific cargo for functional outcomes in development and immune responses. IPO5 displays both spatial and temporal regulation in the male germline, from fetal through to adult ages. Because it transports key early developmental/reproductive factors, including Stella and the BMP signaling SMADs 1/5/9, we hypothesized that targeted IPO5 deletion would impair germline development and viability at specific stages. Here, we demonstrate in vivo functional importance of IPO5 by generating global and conditional IPO5 knockout mice using an Ipo5FL/FL allele flanking exons 9 and 10. Global deletion using CMVCre produced no null embryos at embryonic day (E)12.5, while heterozygous embryo numbers were reduced to 50%, demonstrating it is essential for early embryogenesis. A sex-specific germline requirement for IPO5 was demonstrated following deletion using VasaCre (active from E15.5); adult testes lacked germ cells, while oocytes developed and female fertility was unaffected. Stra8Cre-directed IPO5 deletion (active from postnatal day (PND) 3) caused meiotic failure evident at PND 14; no IPO5-deficient germ cells were present in adults, although niche integrity and function supported emergence of rare IPO5-positive spermatozoa. Novel IPO5 binding proteins identified by immunoprecipitation and mass-spectrometry included SFPQ in fetal testes and XPO2 (exportin 2) in both isolated spermatocytes and spermatids. Remarkably, most IPO5 potential binding proteins are essential for male fertility. These results define IPO5 as crucial for in vivo embryonic development and male fertility. - Source: PubMed
Young Julia CWhiley Penny A FSutherland Jessie MLuu MichaelGarama Daniel JBaker Mark AHogarth Cathryn ARichards Elizabeth AJans David AMcLaughlin Eileen ALoveland Kate L - The Publisher, in agreement with the Editor-in-Chief, is issuing this Expression of Concern to inform readers that a formal investigation is currently underway regarding a set of published articles. Despite multiple attempts to contact the corresponding authors, we have not received any response to date. Further editorial actions, such as retraction or correction, will be taken as appropriate in due course. The articles under investigation fall into the following categories. These studies report extended follow-up periods, yet were published prior to the actual conclusion of the declared follow-up. This discrepancy raises serious concerns about the validity of the timeline and outcome reporting: Liao Y, Cheng S, Xiang J, Luo C. lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients. Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1686-1692. doi: 10.26355/eurrev_201803_14581. PMID: 29630113. Yao N, Sun JQ, Yu L, Ma L, Guo BQ. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4642-4649. doi: 10.26355/eurrev_201906_18043. PMID: 31210289. Hao XZ, Yang K. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7399-7407. doi: 10.26355/eurrev_201909_18848. PMID: 31539127. Jiang J, Wu RH, Zhou HL, Li ZM, Kou D, Deng Z, Dong M, Chen LH. TGIF2 promotes cervical cancer metastasis by negatively regulating FCMR. Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):5953-5962. doi: 10.26355/eurrev_202006_21488. PMID: 32572908. These articles have been questioned as they appear to reuse identical or similar graphical elements and images from a shared library across multiple unrelated studies: Xu CF, Liu P, Tan J, Hu DF. Long noncoding RNA LINC00052 suppressed the proliferation, migration and invasion of glioma cells by upregulating KLF6. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4822-4827. doi: 10.26355/eurrev_201906_18068. PMID: 31210314. Zheng FX, Wang XQ, Zheng WX, Zhao J. Long noncoding RNA HOXA-AS2 promotes cell migration and invasion via upregulating IGF-2 in non-small cell lung cancer as an oncogene. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4793-4799. doi: 10.26355/eurrev_201906_18064. PMID: 31210310. Liao J, Xie N. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A. Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1087-1092. doi: 10.26355/eurrev_201902_16998. PMID: 30779076. Lu J, Xu FQ, Guo JJ, Lin PL, Meng Z, Hu LG, Li J, Li D, Lu XH, An Y. Long noncoding RNA GAS5 attenuates cardiac fibroblast proliferation in atrial fibrillation via repressing ALK5. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7605-7610. doi: 10.26355/eurrev_201909_18883. PMID: 31539152. Shi JQ, Wang B, Cao XQ, Wang YX, Cheng X, Jia CL, Wen T, Luo BJ, Liu ZD. Circular RNA_LARP4 inhibits the progression of non-small-cell lung cancer by regulating the expression of SMAD7. Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):1863-1869. doi: 10.26355/eurrev_202002_20364. PMID: 32141555. Cui K, Zhang H, Wang GZ. MiR-483 suppresses cell proliferation and promotes cell apoptosis by targeting SOX3 in breast cancer. Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2069-2074. doi: 10.26355/eurrev_201903_17248. PMID: 30915751. Ren L, Zhai H, Wang XL, Li JZ, Xia YH. Hsa_circ_0011946 promotes the migration and invasion of hepatocellular carcinoma by inducing EMT process. Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1108-1115. doi: 10.26355/eurrev_202002_20161. PMID: 32096173. Chen RX, Liu HL, Yang LL, Kang FH, Xin LP, Huang LR, Guo QF, Wang YL. Circular RNA circRNA_0000285 promotes cervical cancer development by regulating FUS. Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8771-8778. doi: 10.26355/eurrev_201910_19271. PMID: 31696463. Liu T, Wang W, Xu YC, Li ZW, Zhou J. Long noncoding RNA NEAT1 functions as an oncogene in human laryngocarcinoma by targeting miR-29a-3p. Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6234-6241. doi: 10.26355/eurrev_201907_18442. PMID: 31364125. Liu WG, Xu Q. Long non-coding RNA XIST promotes hepatocellular carcinoma progression by sponging miR-200b-3p. Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9857-9862. doi: 10.26355/eurrev_201911_19549. PMID: 31799653. Weng XD, Yan T, Liu CL. Circular RNA_LARP4 inhibits cell migration and invasion of prostate cancer by targeting FOXO3A. Eur Rev Med Pharmacol Sci. 2020 May;24(10):5303-5309. doi: 10.26355/eurrev_202005_21312. PMID: 32495863. He XY, Pan XM, Jin MM, Yang YL, Yang ZQ, Yan D, Ma JX. Long non-coding RNA AK027294 promotes tumor growth by upregulating PCNA in gastric cancer. Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5762-5769. doi: 10.26355/eurrev_201907_18314. PMID: 31298327. Wang YH, Huo BL, Li C, Ma G, Cao W. Knockdown of long noncoding RNA SNHG7 inhibits the proliferation and promotes apoptosis of thyroid cancer cells by downregulating BDNF. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4815-4821. doi: 10.26355/eurrev_201906_18067. PMID: 31210313. Yang ZT, An F, Hu JD, Zhao WH. Long noncoding RNA AFAP1-AS1 accelerates the proliferation and metastasis of prostate cancer via inhibiting RBM5 expression. Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3284-3290. doi: 10.26355/eurrev_201904_17690. PMID: 31081081. Ma LY, Xie XW, Ma L, Pang JL, Xiong XM, Zheng HD, Shen XL, Wen ZG, Wang HY. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway. Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2626-2634. PMID: 28678322. The following publications have been questioned for showing recurrent structural patterns and visual content (e.g., Kaplan-Meier plots, correlation graphs, etc.) across a large set of articles: Li XF, Aierken AL, Shen L. IPO5 promotes malignant progression of esophageal cancer through activating MMP7. Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4246-4254. doi: 10.26355/eurrev_202004_21004. PMID: 32373960. Gao WY, Yang G, Wang J, He JM, Wang P. CSN6 promotes malignant progression of oral squamous cell carcinoma by down-regulating TIMP-2. Eur Rev Med Pharmacol Sci. 2020 May;24(10):5419-5428. doi: 10.26355/eurrev_202005_21326. PMID: 32495877. Shi XY, Lin JJ, Ge XJ, Shi Y. LncRNA WTAPP1 promotes proliferation of laryngeal carcinoma cells through regulating microRNA-592. Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9532-9540. doi: 10.26355/eurrev_202009_23038. PMID: 33015795. Hou YS, Li X. Circ_0005273 induces the aggravation of pancreatic cancer by targeting KLF12. Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11578-11586. doi: 10.26355/eurrev_202011_23799. PMID: 33275224. Yang Y, Mao FF, Guo L, Guo WX. TRIM56 suppresses the malignant development of hepatocellular carcinoma via targeting RBM24 and inactivating the Wnt signaling. Eur Rev Med Pharmacol Sci. 2021 Jan;25(2):722-730. doi: 10.26355/eurrev_202101_24633. PMID: 33577026. The Publisher apologizes for any inconvenience this may cause. - Source: PubMed
Authors Listed N - Sphingosine and constrained analogs like FTY720 and SH-BC-893 restrain tumor growth through incompletely defined mechanisms that include protein phosphatase 2A (PP2A) activation. Here we show that these compounds directly bind not only the PP2A scaffolding subunit PPP2R1A, but also the structurally related karyopherins importin-β1 (KPNB1), transportin-1 (TNPO1), importin-5 (IPO5), and importin-7 (IPO7). Binding to sphingosine-like molecules triggers reversible unfolding of these target proteins, resulting in activation of PP2A and inhibition of importins. Although sphingosine engages these proteins, ceramide does not, suggesting that these two endogenous tumor-suppressive sphingolipids work through distinct mechanisms. Simultaneous PP2A activation and importin inhibition reduces nuclear levels of proteins that drive cancer progression and therapeutic resistance such as JUN, YAP, MYC, androgen receptor, hnRNPA1, and NF-κB under conditions where compounds that target PP2A or KPNB1 individually are inactive. These findings provide new insights into sphingolipid biology and highlight a possible path toward cancer therapeutics that could overcome drug resistance. - Source: PubMed
Publication date: 2025/06/30
Jayashankar VaishaliKubiniok PeterMcCracken Alison NGentry Rebeca GEckenstein Kazumi HSernissi LorenzoVece VitoGarsi Jean-BaptisteValles Sarah YJung SunheeHoffman Natalie CPerrochon Arielle SSelwan Elizabeth MFinicle Brendan TPitman MaryLin DaWeiBonneil ÉricXu RuijuanMao CunguiKaiser PeterFruman David AMobley DavidJang CholsoonHanessian StephenThibault PierreEdinger Aimee L